Search results for: 'medicine upstream'

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provide insights across new biologics, and precision cancer therapy innovations. The research also comprises small molecule, cell and gene therapy and gene editing advancements for Niemann–Pick Disease and autoimmune diseases.The Life Science, Health & Wellness ...

01 Mar 2024  |  North America  |  Market Research

Global Orphan Drug Growth Opportunities

Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

Infographics

×

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...

This market insight discusses the rheumatoid arthritis pharmaceutical drugs currently in the global market as well as those in the development stage. It offers a competitive analysis of the drugs and a forecast of their impact on the market. Drugs in the development stage are segmented by clinical trial phase as well as by drug class. The study cov...

The continued development of new treatments associated with the demographic trends and public health considerations is remarkable. Nanotechnology has been identified as one most relevant key enabling technologies of the last ten years, significantly impacting on many different biomedical developments in a broad spectrum of applications therapeutics...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision medicine. It highlights AI-driven platforms, advanced biologics, and digital health solutions that address critical challenges in accessibili...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations transforming precision therapeutics, regenerative medicine, AI-enabled discovery, laboratory automation, targeted delivery, vaccines, and biomanufacturing across oncology, chronic disease, neurologica...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping drug discovery, diagnostics, and therapeutic delivery across oncology, infectious diseases, rare and metabolic disorders, neuromuscular and neurodegenerative conditions, diabetes, ophthalmol...

The molecular diagnostics industry is undergoing consolidation, requiring capital investment and faster regulatory pathways to accelerate clinical adoption. Major diagnostics and life sciences companies are acquiring proprietary testing platforms to strengthen positions in precision oncology and blood-based diagnostics. AI-enabled genomic workflow ...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights into recent technological developments for molecular marker detection, drug delivery, cancer immunotherapies and radiopharmaceuticals. The TOE also comprises analysis of innovations across cell and gene therapy, antibody and gene editing platfo...